Initially, genetic testing was funded by state health departments, and individual family cancer clinics (FCCs) determined the criteria used locally to guide the offer of a BRCA1/2 genetic test to women affected by breast and/or ovarian cancer. This evidence concerns the gene BRCA1 and ovarian carcinoma.